Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 147Cholangiocarcinoma 26Liver Neoplasms 17Stomach Neoplasms 13Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 7Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Liver Diseases 3Esophageal Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Carcinoma 3Advanced Biliary Tract Cancer 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Glandular and Epithelial 2Melanoma 2Hepatitis B 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms Immunotherapy 2Uterine Cervical Neoplasms 1

Interventions

tislelizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System × lenvatinib × Gastrointestinal × Clear all
NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡